Science

Revolutionizing delivery
across the blood-brain barrier.

Our Platform: TRACER

Reaching CNS targets once thought unreachable.

Voyager’s TRACER™ (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) capsid discovery platform is a broadly applicable, RNA-based screening platform that enables rapid discovery of AAV capsids with robust penetration of the blood-brain barrier and enhanced central nervous system (CNS) tropism in multiple species, including non-human primates (NHPs).

Learn More About TRACER

Non-Viral Approaches

Multiple modalities to treat neurological diseases.

The Voyager team has expertise in the discovery and development of monoclonal antibodies as well as in receptor-mediated non-viral delivery to the central nervous system.

“I love how we all get to collaborate, even though we are on different teams.”

Gretchen Rivera, Research Associate II, Vector Genome

Voyager_publications_img

Recent Publications & Presentations

ASGCT 2024: Friday, May 10th

Intravenous administration of BBB-penetrant, MAPT-Silencing, AAV gene therapy provides broad and robust CNS Tau lowering in tauopathy mouse models

Intravenous delivery of AAV gene therapy for the treatment of SOD1-ALS provides broad SOD1 lowering in NHP

Evaluation of cross-species expression across four species and cellular tropism of VCAP-102, an engineered blood-brain barrier-penetrating AAV derived capsid from TRACER Platform screens

View All

Our Pipeline

Transforming breakthrough science into medicines.

Partnerships

Our allies in realizing the potential of neuro-genetic medicines

Partner_Logo_White_Alexion

Partner_Logo_White_Neurocrine

Partner_Logo_White_Novartis

Partner_Logo_White_Sangamo